ANI PHARMACEUTICALS INCORPORATED (ANIP)

Calendar & Research Financial Calendar Earnings Calendar & Reports Analyst Ratings Fund Letters Archive Transcripts Search Stock Market Holidays ... Stephen Carey, Senior Vice President and Chief Financial Officer of ANI Pharmaceuticals Inc ANIP, sold 2,850 shares of the company on July 29, ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) CFO Stephen Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00.

Interestingly, the stock is up 28.9% since reporting and currently trades at $17.68. Is now the time to buy Amneal? Access our full analysis of the earnings results here, it's free. With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASD…

ANI Pharmaceuticals recently reported positive topline results from its Phase 4 SYNCHRONICITY trial of the Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis affecting the posterior segment, with both 6‑month co-primary endpoints in visual acuity and retinal thickness ...

Ani Pharmaceuticals (ANIP) stock was recently in focus after the company reported statistically significant topline results from its Phase 4 SYNCHRONICITY trial of a fluocinolone acetonide intravitreal implant for chronic non infectious posterior segment uveitis.